RTP Mobile Logo
Hematologic Oncology Update, Issue 3, 2015
Released January 2016

Featuring interviews with Drs Steven Coutre, David P Steensma, Philippe Moreau and Peter Martin. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    The treatment of hematologic cancer remains a challenge for many healthcare professionals despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given individual requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments and the perspectives of experts, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.

    LEARNING OBJECTIVES

    • Reevaluate your current treatment approach for patients with myeloproliferative disorders and acute and chronic leukemias in light of newly emerging clinical data.
    • Customize the selection of systemic therapy for patients with newly diagnosed and progressive mantle-cell lymphoma, recognizing the recent addition of bortezomib, lenalidomide and ibrutinib as FDA-endorsed options.
    • Develop a rational plan to incorporate B-cell receptor signaling inhibitors and novel CD20 monoclonal antibodies into the treatment of chronic lymphocytic leukemia and other B-cell neoplasms.
    • Incorporate newly approved agents and strategies in the treatment of newly diagnosed and relapsed or refractory multiple myeloma.
    • Develop an understanding of the biologic rationale for and early efficacy data with the use of immunotherapeutic approaches for patients with various hematologic cancers.
    • Recognize the benefits of ongoing clinical trials for patients with hematologic cancers, and inform appropriately selected patients about these options for treatment.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains both audio and print components.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr CoutreAdvisory Committee: Celgene Corporation; Consulting Agreement: Janssen Biotech Inc; Contracted Research: AbbVie Inc, Celgene Corporation, Gilead Sciences Inc, Pharmacyclics Inc, Takeda Oncology. Dr SteensmaAdvisory Committee: Amgen Inc, Celgene Corporation, Genoptix Inc. Dr MoreauAdvisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology. Dr MartinConsulting Agreements: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Idera Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation; Speakers Bureau: Genentech BioOncology.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Pharma Global Development Inc, Celgene Corporation, Genentech BioOncology, Incyte Corporation, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Seattle Genetics, Takeda Oncology and Teva Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2016
    Expiration date: January 2017

Acknowledge and close

Listen to audio:
Hematologic Oncology Update, Issue 3, 2015
Released January 2016

Featuring interviews with Drs Steven Coutre, David P Steensma, Philippe Moreau and Peter Martin. (Text and Audio Content)

Read print: